Journal of Managed Care & Specialty Pharmacy,
Год журнала:
2024,
Номер
30(8-a Suppl), С. S1 - S10
Опубликована: Авг. 1, 2024
AMCP
convened
a
panel
of
clinical
and
managed
care
experts
to
identify
insights
regarding
the
prevalence,
manifestations,
management
approaches
for
immunoglobulin
E-mediated
food
allergies.
This
article
aims
summarize
expert
perspectives
on
health
system
challenges
areas
agreement
concerning
allergies,
advance
payers'
understanding
their
role
in
supporting
patients
with
Food
allergy
requires
dietary
modification
is
associated
significant
patient
caregiver
burdens.
Emerging
therapies
provide
hope
those
living
allergies
but
will
likely
lead
rise
plan
pharmacy
expenses.
In
considering
value
new
treatments,
it
important
consider
total
cost
preventing
anaphylaxis
enhancing
patient's
quality
life.
Several
remain
identifying
appropriate
population
treatment
newer
agents
optimizing
outcomes.
Addressing
disparities
require
standardized
protocols,
better
access
specialized
care,
comorbid
conditions.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(11), С. 3259 - 3259
Опубликована: Май 31, 2024
Food
allergy
(FA)
has
shown
an
increasing
prevalence
in
the
last
decades,
becoming
a
major
public
health
problem.
However,
data
on
of
FA
across
world
are
heterogeneous
because
they
influenced
by
several
factors.
Among
IgE-mediated
FA,
important
role
is
played
related
to
plant-derived
food
which
can
result
from
sensitization
single
protein
(specific
FA)
or
homologous
proteins
present
different
foods
(cross-reactive
including
non-specific
lipid
transfer
(nsLTPs),
profilins,
and
pathogenesis-related
class
10
(PR-10).
In
addition,
clinical
presentation
widely
ranging
mild
symptoms
severe
reactions
up
anaphylaxis,
most
frequently
associated
with
nsLTP-related
(LTP
syndrome).
Considering
potential
life-threatening
nature
patient's
geographical
setting
should
always
be
taken
into
account;
thereby,
it
highly
recommended
build
personalized
approach
for
managing
precision
medicine
era.
For
this
reason,
review,
we
aim
provide
overview
nsLTP-mediated
allergies
Mediterranean
area
point
out
reasons
significance
LTP-driven
particular
focus
allergenic
properties
allergens
their
cross
reactivity.
Allergy and Asthma Proceedings,
Год журнала:
2024,
Номер
45(6), С. 409 - 413
Опубликована: Ноя. 1, 2024
Patients
and
families
living
with
food
allergy
may
experience
significant
burdens,
including
social
isolation,
impaired
quality
of
life,
anxiety.
Allergists/immunologists
play
a
critical
role
in
educating
allergies
about
risk,
particularly
regard
to
the
rarity
fatal
allergy.
Appropriate
risk
framing
can
greatly
decrease
fear-based
burden
disease.
In
2024,
an
increasing
complex
fabric
treatments
has
emerged
that
includes
oral
immunotherapy
(OIT),
sublingual
(SLIT),
omalizumab,
promise
additional
treatments,
epicutaneous
mucosal
near
future.
Younger
children
be
most
likely
benefit
from
OIT
SLIT,
some
evidence
suggests
possibility
immunomodulatory
effect.
Omalizumab,
approved
2024
for
use
conjunction
strict
avoidance,
increases
threshold
reactivity
before
moderate-to-severe
reaction
many,
but
not
all,
patients.
There
is
no
date
omalizumab
effect,
young
treated
monotherapy
bear
lost
opportunity
cost
possible
immunomodulation
would
they
have
been
or
SLIT
instead;
however,
within
shared
decision-making
paradigm,
beyond
label
include
treatment
SLIT.
Fortunately,
co-evolution
modern
will
facilitate
preference-sensitive
care
must
characteristic
all
decisions
surrounding
active
management.
Journal of Managed Care & Specialty Pharmacy,
Год журнала:
2024,
Номер
30(8-a Suppl), С. S1 - S10
Опубликована: Авг. 1, 2024
AMCP
convened
a
panel
of
clinical
and
managed
care
experts
to
identify
insights
regarding
the
prevalence,
manifestations,
management
approaches
for
immunoglobulin
E-mediated
food
allergies.
This
article
aims
summarize
expert
perspectives
on
health
system
challenges
areas
agreement
concerning
allergies,
advance
payers'
understanding
their
role
in
supporting
patients
with
Food
allergy
requires
dietary
modification
is
associated
significant
patient
caregiver
burdens.
Emerging
therapies
provide
hope
those
living
allergies
but
will
likely
lead
rise
plan
pharmacy
expenses.
In
considering
value
new
treatments,
it
important
consider
total
cost
preventing
anaphylaxis
enhancing
patient's
quality
life.
Several
remain
identifying
appropriate
population
treatment
newer
agents
optimizing
outcomes.
Addressing
disparities
require
standardized
protocols,
better
access
specialized
care,
comorbid
conditions.
